Iqvia Hldgs (IQV) Stock News

IQVIA (NYSE:IQV) announced that Dr. William G. Kaelin Jr. joined its board of directors effective November 5, 2025.

Dr. Kaelin is a Nobel Prize winner in Physiology or Medicine (2019), a Senior Physician-Scientist at Brigham and Women’s Hospital, Sidney Farber Professor of Medicine at Dana-Farber and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. He serves on the board of Eli Lilly and chairs its Science and Technology Committee. Dr. Kaelin is an author on hundreds of peer-reviewed publications and holds multiple patents in cancer biology and hypoxia signaling.

NEXT Oncology (IQV) expanded into Japan via a joint venture partnership with Kansai Medical University in Osaka on November 5, 2025. Kansai will offer Phase I oncology trials as part of the NEXT Oncology global network under Director Dr. Toshio Shimizu, who trained in early Phase I drug development with NEXT’s CEO Dr. Anthony W. Tolcher. The Osaka site joins locations across the U.S., Spain, and Brazil. NEXT Oncology treats more than 1,000 patients per year, and the partnership adds Japanese patient access to first‑in‑human and Phase I programs.

IQVIA (NYSE:IQV) reported Q3 2025 revenue of $4,100 million, up 5.2% year‑over‑year (3.9% at constant currency), and GAAP net income of $331 million with GAAP diluted EPS of $1.93.

Adjusted results included Adjusted EBITDA $949 million, Adjusted diluted EPS $3.00, and free cash flow $772 million (up 35% YoY). R&D Solutions reported $2.6 billion in quarterly bookings (book‑to‑bill 1.15x) and a contracted backlog of $32.4 billion. Operating cash flow was $908 million. Net debt totaled $13,143 million and net leverage was 3.52x. The company reaffirmed full‑year 2025 guidance and narrowed ranges on revenue, Adjusted EBITDA, and Adjusted EPS.

IQVIA (NYSE:IQV) announced that Ari Bousbib, chairman and chief executive officer, will speak at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 12:30 p.m. ET. A live audio webcast of the presentation will be available on IQVIA's investor relations website, and a replay will be posted later that day.

This presentation provides investors live access to management commentary on corporate strategy, operations, and recent developments.

IQVIA (NYSE:IQV), a leading global provider of clinical research services and healthcare intelligence, has scheduled its third-quarter 2025 financial results announcement for Tuesday, October 28, 2025, before market opening.

The company will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested participants must pre-register through a provided link to receive dial-in details. The earnings release and presentation materials will be available on IQVIA's investor relations website, with a webcast replay accessible approximately two hours after the event.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, has been awarded the WCG Pinnacle Award for Site Relationships in Professionalism and Communication. The recognition is based on feedback from over 12,000 participants in WCG's 2025 CenterWatch Global Site Relationship Survey.

The survey evaluated organizations across multiple criteria including protocol design, site management, operational efficiency, participant diversity, and technology utilization. Brian O'Dwyer, president of Global Clinical Development at IQVIA, emphasized the importance of human connection and clear communication in achieving operational excellence in clinical research.

IQVIA (NYSE:IQV) has unveiled its Clinical Trial Financial Suite (CTFS), an AI-powered platform designed to streamline financial management in clinical trials. The platform's first module, CTFS Site Payments, aims to automate complex trial processes and is expected to reduce processing time by up to 50%.

The innovative solution integrates budgeting, contracting, forecasting, and payment workflows into a unified system, leveraging agentic AI to automate manual tasks. Built on IQVIA's extensive experience managing site and participant payments across 200+ geographies, CTFS will be commercially available in Q1 2026, following a sandbox release for early adopters in Q4 2025.

IQVIA Holdings (NYSE:IQV) announced a planned CFO transition, with Michael Fedock appointed as Executive Vice President and CFO, effective February 28, 2026. Fedock, currently Senior VP of Financial Planning & Analysis, will succeed Ron Bruehlman, who will transition to a Senior Advisor role to CEO Ari Bousbib.

Fedock brings significant experience from his roles at IQVIA since 2016, including positions as CFO of IQVIA's R&D Solutions and IQVIA Laboratories. Bruehlman, who joined in 2011, played a crucial role in IMS Health's 2014 IPO and the 2016 Quintiles-IMS Health merger, and guided the company through the COVID-19 pandemic after returning from retirement in 2020.

Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.

The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.